Jefferies Assigns 65–75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.’s (DFTX) DT120 in Phase IIIFebruary 19, 2026Yahoo Finance
Analysts Bullish on COMPASS Pathways plc (CMPS) Following Psychedelics Symposium and Model UpdatesFebruary 19, 2026Yahoo Finance
Analysts Bullish on COMPASS Pathways plc (CMPS) Following Psychedelics Symposium and Model UpdatesFebruary 19, 2026Yahoo Finance
Analysts Bullish on COMPASS Pathways plc (CMPS) Following Psychedelics Symposium and Model UpdatesFebruary 19, 2026Yahoo Finance
Analysts Bullish on COMPASS Pathways plc (CMPS) Following Psychedelics Symposium and Model UpdatesFebruary 19, 2026Yahoo Finance
Analysts Bullish on COMPASS Pathways plc (CMPS) Following Psychedelics Symposium and Model UpdatesFebruary 19, 2026Yahoo Finance
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming TrialsFebruary 19, 2026Yahoo Finance
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming TrialsFebruary 19, 2026Yahoo Finance
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming TrialsFebruary 19, 2026Yahoo Finance
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming TrialsFebruary 19, 2026Yahoo Finance
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming TrialsFebruary 19, 2026Yahoo Finance
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)’s Science-Driven Psilocybin Therapies as Key Growth DriversFebruary 19, 2026Yahoo Finance
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)’s Science-Driven Psilocybin Therapies as Key Growth DriversFebruary 19, 2026Yahoo Finance
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)’s Science-Driven Psilocybin Therapies as Key Growth DriversFebruary 19, 2026Yahoo Finance
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)’s Science-Driven Psilocybin Therapies as Key Growth DriversFebruary 19, 2026Yahoo Finance
